HOXB7 8–25
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4+ T cell responses[1].
Product Specifications
Product Name Alternative
MDM2 32-46
UNSPSC
12352209
Target
Ligands for E3 Ligase
Type
Peptides
Related Pathways
PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hoxb7-8-25.html
Solubility
10 mM in DMSO
Smiles
O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CO)C(N[C@@H](C(C)C)C(NCC(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(O)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]1NCCC1
Molecular Formula
C75H135N19O20
Molecular Weight
1622.99
References & Citations
[1]Kono M, et al. Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. Cancer Immunol Immunother. 2021;70 (12) :3421-3434.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
MDM2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog